El interés en corto de Pliant Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Pliant Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Pliant Therapeutics (NASDAQ:PLRX) Bolsa, Informe de interés en corto

Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics Inc

As a result, the Company has decided to voluntarily revise its historical adjusted operating income for the relevant periods, resulting in a decrease in after-tax adjusted operating income of $115 million or $0.31 per Common share for the nine months ended September 30, 2024, and $24 million or $0.07 per Common share for the nine months ended September 30, 2023, compared to previously reported amounts(1).&nbsp;
These revisions had no impact to GAAP net income, book value, statutory results, or the historical or expected future cash flows of these products.

News

Prudential Financial Says Identified An Immaterial Error During Q4 In Application Of Adjusted Operating Income - Filing

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 15 years by 7.09% on an annualized basis producing an average annual return of 18.86%. Currently, Amphenol has a market capitalization of $85.54 billion. 
Buying $1000 In APH: If an investor had bought $1000 of APH stock 15 years ago, it would be worth $12,870.75 today based on a price of $70.95 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736976607_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Dividends

NEXA

Nexa Resources Adopts New Dividend Policy; Targets Annual Dividend Of Up To 20% Of Free Cash Flow Pre-events, With Minimum Payment Of $0.08 Per Share

"Exceptional holiday demand and the effective execution of our strategic initiatives fueled our fourth-quarter outperformance, and gives us confidence that we will exceed our prior 2024 guidance,"&nbsp;stated Charlie Youakim, Sezzle Chairman and CEO.

Guidance

SEZL

Sezzle Expects Exceeding 2024 Revenue And Income Guidance Provided In Conjunction With Its Q3 Earnings Release.

MetLife Responds To Report On Cyberattack, Says "We are aware of a cyberattack impacting Ecuador-based Fondo Genesis. As Fondo Genesis operates separately from MetLife's enterprise systems, this incident has not impacted any other parts of the MetLife business. Fondo Genesis is a financial services company operating only in Ecuador that is owned by Chilean pension manager ProVida, a subsidiary of MetLife."

Mandy Long will step down as Chief Executive Officer and from the Board of Directors, transitioning to serve as a Company advisor.
McAleenan currently serves as BigBear.ai's President.

Management

BBAI

BigBear.ai Appoints Kevin McAleenan As CEO And Member Of  Board, Effective January 15, 2025, Succeeding Mandy Long

Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.52 by 3.85 percent. The company reported quarterly sales of $258.36 million which beat the analyst consensus estimate of $256.70 million by 0.65 percent. This is a 5.19 percent increase over sales of $245.62 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

HOMB

Home BancShares Q4 2024 Adj EPS $0.50 Misses $0.52 Estimate, Sales $258.36M Beat $256.70M Estimate

Compass Diversified Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>), an owner of leading middle market businesses (the "Company" or "CODI"), announced today that on January 15, 2025, it entered into a Seventh Amended and Restated Management Services Agreement with Compass Group Management LLC, the Company's Manager (the "Amendment"). The Amendment, commencing in the first quarter beginning on January 1, 2025, restructures the management fee under the existing Management Services Agreement to consist of a base management fee and an incentive management fee. Pursuant to the Amendment, the base management fee will be (i) 2.0% of the Company's adjusted net assets when the adjusted net assets are less than or equal to $3.5 billion (the "Initial Threshold Fee"), (ii) the Initial Threshold Fee, plus 1.25% of the amount of adjusted net assets exceeding $3.5 billion when the adjusted net assets are more than $3.5 billion but less than $10 billion, or (iii) 1.5% of the Company's adjusted net assets when the adjusted net assets are $10 billion or more.
The incentive management fee will be 0.25% of the amount of adjusted net assets exceeding $3.5 billion, when the adjusted net assets are more than $3.5 billion but less than $10 billion. The incentive management fee is only earned if the Company's annualized internal rate of return on equity for the trailing three years exceeds 12%. Such incentive management fee is also subject to approval by the Compensation Committee of the Company's Board of Directors.

CODI

Compass Diversified Enters Seventh Amended Management Services Agreement, Restructures Fees Effective Q1 2025; Base Fee 2% Up To $3.5B, 1.25% Over $3.5B to $10B, 1.5% Over $10B; Incentive Fee 0.25% Over $3.5B To $10B Subject To 12% Return Approval

O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) has outperformed the market over the past 5 years by 9.93% on an annualized basis producing an average annual return of 22.27%. Currently, O'Reilly Automotive has a market capitalization of $69.51 billion. 
Buying $100 In ORLY: If an investor had bought $100 of ORLY stock 5 years ago, it would be worth $273.27 today based on a price of $1204.04 for ORLY at the time of writing.
<h3>O'Reilly Automotive's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736975709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLY

Here's How Much You Would Have Made Owning O'Reilly Automotive Stock In The Last 5 Years

Additionally, Capital Southwest's preliminary estimate of its net asset value per share as of December 31, 2024 is in the range of $16.57 to $16.62. Finally, Capital Southwest's preliminary estimate of its investment assets at fair value as of December 31, 2024 is approximately $1.7 billion.

CSWC

Capital Southwest Reveals Preliminary Estimate Of Q3 Pre-tax Net Investment Income Of $0.63 - $0.64 Per Shae; Sees Net Investment Income Of $0.62 - $0.63 Per Share; Est $0.62

Fiscal 2025 Outlook:
<ul>
<li>Net revenue growth for fiscal 2025 is expected to be down 2% to 4%, adjusting for the divestiture of the Flooring business, net revenue is expected to be up 1% to 2%;</li>
<li>Organic revenue growth is expected to be flat to up 2% versus fiscal 2024;</li>
<li>Adjusted EBITDA for fiscal 2025 is expected to be in the range of $600 million to $625 million, equating to growth of approximately 1% to 5% year-on-year;</li>
<li>Adjusted EBITDA for the first quarter of 2025 is expected to be in the range of $105 million to $115 million;</li>
<li>The core tax rate, excluding the impact of discrete items, is anticipated to be between 26% and 27% in fiscal year 2025;</li>
<li>Net interest expense for fiscal 2025 is expected to be between $120 million and $125 million;</li>
<li>Adjusted EPS (diluted) is expected to be in the range of $3.90 to $4.20, equating to a range of up 2% to 9% year-on-year;</li>
<li>Operating cash flow in fiscal year 2025 is expected to be between $300 million and $325 million;</li>
<li>Capital expenditures of approximately $160 million are expected in fiscal 2025, which includes approximately $40 million related to the Company's manufacturing footprint consolidation initiative.</li>
</ul>

H.B. Fuller Fiscal 2025 Outlook, Sees Net Revenue Down 2%-4%; Organic Growth Flat To Up 2%; Adjusted EBITDA $600M-$625M, Q1 $105M-$115M; Adj. EPS $3.90-$4.20 Vs $4.22 Est.; Cash Flow $300M-$325M

Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) could share more commentary on strong semiconductor demand and how a new White House administration could boost the sector when the company reports fourth-quarter financial results before <a href="https://www.benzinga.com/earnings">the market opens Thursday.</a>
Earnings Estimates: Analysts expect Taiwan Semiconductor to report fourth-quarter revenue of $26.28 billion. That&#8217;s up from $19.62 billion in last year's fourth quarter, according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in four straight quarters and five of the last 10 quarters overall.
Analysts expect the company to report fourth-quarter earnings per share of $2.23, up from $1.44 in last year's fourth quarter. The company beat analyst earnings per share estimates in four straight quarters and six of the last 10 quarters overall.
Guidance from the company provided after Q3 results called for fourth-quarter revenue of $26.1 billion to $26.9 billion.
What Analysts Are Saying: Strong demand for leading-edge nodes from the company could power fourth-quarter results and 2025 guidance, Goldman Sachs analyst Bruce Lu <a href="https://www.benzinga.com/25/01/42825523/taiwan-semi-likely-for-upside-backed-by-ai-demand-and-advanced-node-pricing-analyst-says">recently said.</a>
The analyst maintained a Buy rating and raised the price target from $248 to $254.
Lu sees strong momentum in artificial intelligence helping to boost revenue for Taiwan Semiconductor in 2025.
The analyst also sees a more favorable landscape for Taiwan Semiconductor against competitors like Samsung Electronics and Intel as those companies move to more advanced nodes.
Taiwan Semiconductor could raise prices and see its gross margins grow in 2025, the analyst added.
Read Also: <a href="https://www.benzinga.com/25/01/42917194/tsmc-powers-up-december-revenue-soars-ahead-of-q4-earnings-release">TSMC Powers Up: December Revenue Soars Ahead Of Q4 Earnings Release</a>
Key Items to Watch: Analysts and investors will be watching for commentary from Taiwan Semiconductor on recent reports of increased export regulations to China.
Advanced chips, including those that specialize in AI, have been a hot topic among items that are banned from being exported to China under <a href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report">the Biden administration</a>.
Trump is set to take office on Monday, a short time after Taiwan Semiconductor's earnings report is published. Analyst questions could center on the political conversation of the semiconductor sector and what's ahead.
The semiconductor sector saw several stocks as top performers in 2017 — Trump&#8217;s first year in the White House previously. Micron Technology and Nvidia Corporation were among the <a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r">10 best-performing stocks</a> in 2017 among S&amp;P 500 members.
Investors and analysts may also be looking for an update on Taiwan Semiconductor's U.S. expansion. The company expects its Arizona plant <a href="https://www.benzinga.com/government/regulations/25/01/42947562/taiwan-semiconductor-begins-4nm-chip-production-in-arizona-eyes-11-4-billion-q4-profit">to begin manufacturing </a>in 2025.
Price Action: Taiwan Semiconductor stock is up 2% to $206.06 on Wednesday versus a 52-week trading range of $100.000 to $222.20. Taiwan Semiconductor stock is up 103% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43003008/taiwan-semi-samsung-intel-may-face-stricter-us-rules-on-chip-exports-to-china-over-security-concerns">Taiwan Semi, Samsung, Intel May Face Stricter US Rules on Chip Exports to China Over Security Concerns</a></li>
</ul>
Image: Shutterstock

Previews

Tech

Taiwan Semiconductor Q4 Earnings Preview: Analysts Expect 5th Straight Beat, Will Execs Comment On Trump Impact?

The World Economic Forum's (WEF) "Global Risks Report" for 2025 paints a sobering picture of the challenges ahead. The survey, released during the <a href="https://www.benzinga.com/topic/world-economic-forum#more-news">WEF&#8217;s annual meeting in Davos</a>, Switzerland, highlights the risks of geopolitical tensions, climate change and disinformation. 
These risks call for strategies to safeguard investments while capitalizing on emerging opportunities. Here&#8217;s how some ETFs could help investors sail smoothly through each global challenge mentioned in the survey.
Armed Conflict
According to the WEF report, 23% of respondents named state-based armed conflict as the most pressing risk for 2025. Persistent geopolitical tensions, such as the Russia-Ukraine conflict and the unrest in the Middle East, have shaken global trust.
In such a dire situation, defense ETFs and global security ETFs can save the day for investors. iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) provides exposure to U.S.-based companies in the defense sector, which could benefit from increased government spending on military capabilities. Moreover, an expense ratio of 0.4% makes it a cost-effective option. Also, a beta of 0.97% means it is at slightly lower risk than the broader market during volatility.
In addition, the SPDR S&amp;P Kensho Future Security ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITE#NYSE">FITE</a>) focuses on innovative companies addressing global security challenges, including cybersecurity and physical defense. A glimpse of its top holdings include Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>), Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) and F5 Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>). The fund boasts an expense ratio of 0.45%.
Extreme Weather
The climate crisis is intensifying the frequency and severity of weather events such as floods, heatwaves, and tornadoes. With environmental risks dominating the 10-year horizon, resilient investment strategies are the need of the hour.
Clean Energy ETFs are well-positioned to capitalize on this global challenge. Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) has holdings in solar energy companies like Enphase Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NYSE">ENPH</a>) and First Solar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>), which are poised to benefit from global decarbonization efforts.
See Also: <a href="https://www.benzinga.com/news/24/10/41594398/bill-gates-climate-innovation-model-wins-praise-from-ray-dalio-klaus-schwab-but-say-1-trillion-annua">Bill Gates&#8217; Climate Innovation Model Wins Praise From Ray Dalio, Klaus Schwab, But Say $1 Trillion Annual Funding Globally Is Not Enough</a>
Disinformation and Misinformation
For the second consecutive year, the scourge of misinformation and disinformation has been flagged by WEF as a top risk, leading to societal distrust, markets disruption, and heightened polarization. 
Many tech companies are united in their efforts to curb the spread of misinformation as well as disinformation (there is a very thin line of intentions separating the two terms). However, among those most equipped to fight this menace are cybersecurity companies. Naturally, <a href="https://www.benzinga.com/25/01/42829188/hack-attack-cybercrime-surge-fuels-demand-for-cybersecurity-etfs">ETFs focusing on the cybersecurity sector</a> stand to gain.
First Trust Nasdaq Cybersecurity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>) focuses on companies addressing cyber threats, which often fan the fire of misinformation. Stocks of companies like Broadcom, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Crowdstrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) and Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), prominent players in the cybersecurity space, are part of this fund&#8217;s holdings. 
Media ETFs like the Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) can also benefit from media firms, which are increasingly becoming content-conscious. Media firms may benefit from investing in trusted content creation and digital information technologies.
Why ETFs Are Ideal In Turbulent Times
Insights from over 900 global risk experts, policymakers and industry leaders in September and October last year were obtained to compile WEF&#8217;s survey report. Some of the other short-term risks that the WEF's report highlights include societal polarization, cyber espionage, pollution, and inequality.
In these turbulent times, investors seek to hedge their investments instead of holding back from the market. ETFs come into the picture as flexible, cost-efficient and concern-specific instruments that allow investors to diversify their portfolios across sectors and geographies during global uncertainties.
As Carolina Klint of Marsh McLennan Europe told CNBC, "I think we're navigating an era now marked by increasing economic tensions&#8230;And I think we have to recognize the fragmentation is not a theoretical concern. It is something that we need to confront today. So, it has resulted in a more complex and uncertain trading environment." 
Building a resilient portfolio with ETFs aligned to global challenges can help investors power through 2025.
See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/01/43010401/maximize-growth-minimize-risk-with-new-dynamic-allocation-etf">Maximize Growth, Minimize Risk With New, Dynamic Allocation ETF</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Emerging Market ETFs

Global

ETFs

ANEW

AVGO

CIBR

CRWD

CSCO

ENPH

FFIV

FITE

FSLR

iShares Dow Jones US Aerospace & Defense Index Fund

VSAT

Davos 2025: ETFs To Tackle Geopolitical, Climate, Cyber Risks

The Q4 earnings report for H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) was released on Wednesday, January 15, 2025 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
H.B. Fuller missed estimated earnings by -8.0%, reporting an EPS of $0.92 versus an estimate of $1.0.
Revenue was up $20.41 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company missed on EPS by $0.1 in the last quarter, resulting in a 0.0% increase share price change the following day.
Here's a look at H.B. Fuller's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.23</td>
<td>1.03</td>
<td>0.64</td>
<td>1.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.13</td>
<td>1.12</td>
<td>0.67</td>
<td>1.32</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>944.25M</td>
<td>913.23M</td>
<td>825.03M</td>
<td>932.16M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>917.93M</td>
<td>917.11M</td>
<td>810.42M</td>
<td>902.88M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
H.B. Fuller management provided guidance for FY 2024, expecting earnings between $3.84 and $3.84 per share.
To track all earnings releases for H.B. Fuller <a href="https://www.benzinga.com/quote/FUL/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

H.B. Fuller Earnings Report: Q4 Overview

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) reported its Q4 earnings results on Wednesday, January 15, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Concentrix beat estimated earnings by 8.0%, reporting an EPS of $3.26 versus an estimate of $3.01.
Revenue was up $217.00 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
In the previous quarter, the company missed on EPS by $0.06, resulting in a 19.0% drop change in the share price the following day.
Here's a look at Concentrix's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.93</td>
<td>2.62</td>
<td>2.58</td>
<td>3.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.87</td>
<td>2.69</td>
<td>2.57</td>
<td>3.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.38B</td>
<td>2.35B</td>
<td>2.38B</td>
<td>2.20B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.39B</td>
<td>2.38B</td>
<td>2.40B</td>
<td>2.23B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Concentrix <a href="https://www.benzinga.com/quote/CNXC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNXC

Concentrix: Q4 Earnings Insights

Biotech

General

Eli Lilly Announces The FDA Has Approved Omvoh For The Treatment Of Moderately To Severely Active Crohn's Disease in Adults

WIIM

PMAX

Powell Max shares are trading higher after the company announced acquisition plans and is targeting firms with between $1 million and $5 million in revenue to expand into the Hong Kong and Asian financial communications market.

Concentrix shares are trading lower following soft guidance.

Concentrix Sees Q1 Non-GAAP EPS $2.49-$2.64 vs $2.85 Est., Revenue $2.355B-$2.370B vs $2.409B Est.; Sees FY25 Non-GAAP EPS $11.18-$11.77 vs $11.97 Est., Revenue $9.470B-$9.610B vs $9.726B Est.

- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
- FA: First-in-human clinical study of SGT-212 utilizing a dual route of administration to treat Friedreich's ataxia (FA) anticipated in 2H 2025 following recent FDA IND clearance -
- CPVT: Submission of IND for SGT-501 on track for 1H 2025; the submission will expand clinical-stage portfolio to three unique candidates in diverse indications with significant unmet need -
- Cash: Company enters 2025 with approximately&nbsp;$148.9 million&nbsp;in cash and investments1 as of 12/31/2024; expected to fund key strategic priorities into 2026 -
CHARLESTOWN, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will provide a corporate update outlining the Company's expanded clinical-stage pipeline and 2025 objectives as it completes its transformation into a multi-program leader in the development of precision genetic medicines. Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will provide the update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).

SLDB

Solid Biosciences Announces Clinical Pipeline Updates: SGT-003 Tolerated In Duchenne Trial; SGT-212 FA Study For 2H 2025; SGT-501 IND Submission By H1 2025; $148.9M Cash Funding Through 2026

Pliant Therapeutics GAAP EPS of -$0.95

Needham analyst Joseph Stringer has maintained their bullish stance on PLRX stock, giving a Buy rating yesterday. Joseph Stringer's rating is based...

Positive Outlook on Pliant Therapeutics: Strategic Developments and Financial Stability Support Buy Rating

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), with a pri...

RBC Capital Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of $45.00. The ...

Oppenheimer Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C...

Positive Clinical Progress and Promising Data Support Buy Rating for Pliant Therapeutics

Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of ...

Buy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market Positioning

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $43...

Promising Pipeline and Strong Financials Reinforce Buy Rating for Pliant Therapeutics

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q3 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to i...

Pliant Therapeutics Reports Increased Losses and Strategic Focus

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price target o...

Positive Developments in Pliant Therapeutics' IPF Research Bolster Buy Rating

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), with a price...

Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)

PLRX

Health Care

Press Releases

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

Comments

Pliant Therapeutics

Interés en corto

Pliant Therapeutics (NASDAQ:PLRX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL